Search Results 1411-1420 of 19113 for autoimmune hepatitis

  1. Tocilizumab-Bavi (Intravenous Route) Before Using - Mayo Clinic

    Infections (eg, hepatitis B, bacteria, virus, fungus), active or recurring or · Liver disease, active—Should not be used in patients with these conditions.

  2. Ipratropium (Nasal Route) Before Using - Mayo Clinic

    May make these conditions worse. Kidney disease or; Liver disease—Use with caution. This medicine has not been studied in patients with these conditions.

  3. Efavirenz, Lamivudine, And Tenofovir (Oral Route) Before Using - Mayo Clinic

    Hepatitis B infection, history of or; Hypercholesterolemia (high cholesterol level in the blood) or; Kidney failure, acute or; Liver disease, mild or; Mental ...

  4. Elivaldogene Autotemcel (Intravenous Route) Before Using - Mayo Clinic

    Hepatitis A Vaccine, Inactivated; Hepatitis B Vaccine; Human Papillomavirus ... Liver disease—Use with caution. This medicine has not been studied in ...

  5. Understanding HCV and evolving treatment guidelines - Mayo Clinic

    Hepatitis C virus (HCV) infection can lead to cirrhosis and its related complications, hepatocellular carcinoma (HCC), liver failure and death.

  6. Birth control patch - Mayo Clinic

    Have liver disease or migraines with aura; Have diabetes-related complications of the kidneys, eyes, nerves or blood vessels; Have unexplained vaginal ...

  7. Pentazocine (Injection Route) Before Using - Mayo Clinic

    Kidney disease or · Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

  8. High red blood cell count - Mayo Clinic

    This causes the body to make more red blood cells. Red blood cell counts also can be high in nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease.

  9. Funding - Translational Cardiovascular Disease Research Laboratory - Mayo Clinic Research

    Autoimmune mechanisms in human myocarditis, NIH, NHLBI (R01 HL135165), 1/1/2017-12/31/2021. More about research at Mayo Clinic. Research Faculty · Laboratories ...

  10. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

    alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease. - Patients with past or resolved hepatitis B infection (defined as having a